SLRX — Salarius Pharmaceuticals Income Statement
0.000.00%
- $1.09m
- -$3.16m
Annual income statement for Salarius Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.47 | 5.23 | 1.84 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 11.7 | 13 | 14.7 | 31.8 | 12.9 |
Operating Profit | -8.27 | -7.79 | -12.8 | -31.8 | -12.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.94 | -7.35 | -12.8 | -31.6 | -12.5 |
Net Income After Taxes | -6.94 | -7.35 | -12.8 | -31.6 | -12.5 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -6.94 | -7.35 | -12.8 | -31.6 | -12.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.94 | -7.75 | -12.8 | -31.6 | -12.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -425 | -99.5 | -61.7 | -85.6 | -30.7 |